Recursion Pharmaceuticals (NASDAQ:RXRX) Reaches New 52-Week Low – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price reached a new 52-week low during trading on Friday . The stock traded as low as $2.98 and last traded at $2.9950, with a volume of 7938989 shares traded. The stock had previously closed at $3.15.

Analyst Upgrades and Downgrades

RXRX has been the topic of several recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 26th. JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $10.00 to $11.00 in a report on Wednesday, December 17th. Morgan Stanley set a $11.00 price objective on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Stock Down 7.5%

The company has a quick ratio of 5.50, a current ratio of 5.50 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $1.54 billion, a PE ratio of -1.98 and a beta of 0.97. The stock has a 50-day moving average of $3.77 and a 200 day moving average of $4.49.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.07. The business had revenue of $35.54 million for the quarter, compared to analysts’ expectations of $24.56 million. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The business’s revenue was up 671.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.53) earnings per share. Sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 28,298 shares of Recursion Pharmaceuticals stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $3.35, for a total value of $94,798.30. Following the sale, the chief executive officer owned 2,262,085 shares of the company’s stock, valued at approximately $7,577,984.75. The trade was a 1.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Ben R. Taylor sold 21,383 shares of the business’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $4.18, for a total transaction of $89,380.94. Following the completion of the transaction, the chief financial officer owned 761,550 shares in the company, valued at approximately $3,183,279. The trade was a 2.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 511,063 shares of company stock valued at $2,135,702. 8.43% of the stock is owned by insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently modified their holdings of RXRX. TD Waterhouse Canada Inc. lifted its stake in Recursion Pharmaceuticals by 64.1% in the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after purchasing an additional 2,200 shares during the last quarter. Xponance Inc. increased its position in Recursion Pharmaceuticals by 8.0% in the third quarter. Xponance Inc. now owns 30,020 shares of the company’s stock worth $146,000 after buying an additional 2,221 shares during the last quarter. NewEdge Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 28.1% in the second quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock valued at $56,000 after buying an additional 2,428 shares during the period. Equitable Holdings Inc. raised its stake in shares of Recursion Pharmaceuticals by 7.1% in the third quarter. Equitable Holdings Inc. now owns 39,400 shares of the company’s stock valued at $192,000 after buying an additional 2,600 shares during the period. Finally, Cherry Creek Investment Advisors Inc. lifted its position in shares of Recursion Pharmaceuticals by 4.1% during the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 66,781 shares of the company’s stock valued at $326,000 after buying an additional 2,649 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.